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Gefitinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, is effective in
treating patients with non-small cell lung cancer (NSCLC) after unsuccessful chemotherapy.
However, survival outcomes and predictors for its effectiveness in chemotherapy-naive NSCLC
patients are still not clear. The goal of this study was to investigate the response and survival
rates and identify the predictive factors for patients with advanced or metastatic disease receiv-
ing gefitinib as first-line therapy. We retrospectively analyzed the response and survival rates of
patients with advanced or metastatic NSCLC who had received gefitinib as first-line therapy
across six medical institutes in Southern Taiwan between May 2004 and April 2006. The relation-
ship between the response and survival rates to the known predictive factors for gefitinib
response and survival was also investigated. A total of 97 patients (65 females and 32 males) were
enrolled in this study. Seventy-four patients (76%) had never smoked. Eighty-eight patients
(91%) had adenocarcinoma or bronchioloalveolar cell carcinoma. The objective response rate was
56% and the disease control rate (partial response plus stable disease) was 76%. Only poor per-
formance status (Eastern Cooperative Oncology Group score, 3–4) was statistically significantly
associated with overall response in this study. The 1-year survival rate was 77%. We suggest that
first-line gefitinib monotherapy is promising in some subgroups of Asian patients with NSCLC.
Further randomized controlled studies are needed to validate the effectiveness of first-line gefitinib
therapy.
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Lung cancer is one of the most common malignancies
in many countries, including Taiwan. It remains the
leading cause of cancer-related deaths in these coun-
tries [1,2]. The incidence of lung cancer is increasing
annually, particularly among women [3]. Lung cancer
is classified according to histological type as either
small cell carcinoma or non-small cell lung cancer
(NSCLC), the latter accounting for about 85% of all
lung cancer cases [4,5], and consists of large cell carci-
noma, adenocarcinoma, and squamous cell carcinoma.
Surgery, chemotherapy and radiotherapy are the
primary treatment options for patients with NSCLC.
Unfortunately, less than 20% of patients are suitable
for potentially curative resection at presentation [6,7].
Around 70% of patients have locally advanced or dis-
seminated disease at presentation, are not candidates
for surgery [8] and are generally treated with palliative
chemotherapy. The prognosis for patients not suitable
for surgery remains unsatisfactory. Thus it is neces-
sary to explore new therapeutic modalities to treat
this devastating disease.
Gefitinib [Iressa (ZD1839); AstraZeneca Pharma-
ceuticals, Wilmington, DE, USA] is a selective epider-
mal growth factor receptor (EGFR) tyrosine kinase
inhibitor. After two large-scale phase II studies show-
ing that gefitinib was beneficial in terms of response
for patients with locally advanced or metastatic
NSCLC who had previously received platinum-based
chemotherapy [9,10], gefitinib was approved for the
treatment of patients with previously treated advanced
NSCLC in Japan, the United States of America and
other countries [11]. Unfortunately, two multina-
tional, randomized, double-blind, placebo-controlled
phase III studies failed to demonstrate improved tumor
response rate or survival rate for gefitinib in combi-
nation with standard platinum-based first-line chemo-
therapeutic regimens [12,13]. In addition, in a large
randomized, placebo-controlled trial, gefitinib mono-
therapy failed to increase survival of chemotherapy-
resistant patients [14]. However, in the same study, 
a statistically significant improvement in overall sur-
vival was noted in gefitinib-treated patients over
placebo-treated patients with Asian ethnicity. These
findings are consistent with the better response rate
reported in Japanese patients in one of the phase II
studies, the Iressa Dose Evaluation in Advanced
Lung Cancer study [9]. In addition to the beneficial
effects of gefitinib in chemotherapy-treated NSCLC
patients, there have been several small, single-arm
studies in Asia showing the effectiveness of gefitinib
in chemotherapy-naive NSCLC patients [15–17].
Based on its effectiveness and good safety profile,
an increasing number of patients with NSCLC in
Taiwan have been using gefitinib as first-line therapy.
In this study, we retrospectively analyzed the response
and 1-year survival of patients with advanced or
metastatic NSCLC who used gefitinib as first-line
treatment across six medical institutes in Southern
Taiwan. We examined the response and survival rates
of these patients and the relationship between these
rates and known predictive factors.
METHODS
Patients
All stage IIIB or IV NSCLC patients who received gefi-
tinib as their first-line therapy at one of the six insti-
tutes in Southern Taiwan between May 2004 and April
2006 were included in this study. Their medical charts,
images and image reports were reviewed. Patients
were required to meet the following inclusion citeria:
cytological or histological diagnosis of NSCLC [stage
IIIB (with pleural effusion) or IV disease] and an age
> 18 years. Patients must also have had measurable
lesion(s). Patients who were administered gefitinib
for less than 1 month and patients with symptomatic
brain metastases were excluded from this study.
Clinical data were collected from each institute’s reg-
istry and included the patient’s sex, age, Eastern
Cooperative Oncology Group (ECOG) performance
status, tumor histology, tumor stage, smoking status,
dates of diagnosis, treatment, progression, death and
follow-up.
Efficacy assessment
Objective tumor response was assessed by chest 
X-rays of these patients performed at least 4 weeks
after treatment, using the Response Evaluation
Criteria in Solid Tumors system [18], which defined
responses as complete response, partial response
(PR), stable disease (SD) or progressive disease (PD).
Statistical methods
A total of 97 patients met the criteria and were
included in this study. Two definitions of response to
gefitinib were used in this study: overall response and
disease stabilization. The associations between these
and factors such as sex, smoking history, histology,
disease stage and performance status were examined
with χ2 tests and odds ratios were calculated using
logistic regression to evaluate associations with the
response. Logistic regression models, including fac-
tors with p values < 0.15, were developed to adjust 
for possible confounding effects and identify the
major predictors for the response. For survival status, 
1-year survival rates were computed and the Cox
proportional-hazards model was used to determine
the associations of these factors with mortality.
Adjusted hazard ratios were calculated, and these
included factors with p values < 0.15.
RESULTS
Of these 97 patients, no patient had a complete
response. For 54 patients, the best response to gefi-
tinib was PR, corresponding to an objective response
rate of 56%. Another 19 patients had SD and the overall
disease control rate (PR + SD) was 76%. The charac-
teristics of these patients are summarized in Table 1.
For overall response, sex, smoking history, stage and
poor performance status seemed to be predictors.
However, only poor performance status (ECOG score,
3–4) was statistically significantly associated with over-
all response [odds ratio: 0.26, 95% confidence interval
(CI): 0.09–0.75, p=0.009]. For disease stabilization, sex,
performance status, smoking history and stage seemed
to be predictors, but sex was not statistically related
to disease stabilization.
For survival status, the 1-year survival rates and
hazard ratios are shown in Table 2. For all 97 patients,
the mean follow-up time was 43.2 weeks and the
mean 1-year survival rate was 77%. Predictors such
as sex, ECOG performance status, smoking status
and stage seemed to be associated with survival. The
hazard ratio (95% CI) was 2.34 (0.90–6.07) for sex
(male vs. female); 8.32 (3.10–22.36) for ECOG per-
formance status (0–2 vs. 3–4); 3.02 (1.16–7.85) for
smoking status (ever smoker vs. never smoker) and
7.36 (0.95–55.88) for stage (IIIB vs. IV). Patients who
showed response or stabilization with gefitinib also
had a higher 1-year survival rate compared with
patients with PD (94% and 89.7% vs. 45.9%, respec-
tively). The HR (95% CI) was 0.06 (0.01–0.26) 
for patients with PR versus patients with PD and 
0.14 (0.05–0.38) for patients with SD versus patients
with PD.
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Table 1. Characteristics and gefitinib treatment response of the patients*
Characteristics Patients
Overall OR 
p
Disease OR 
p
response (95% CI) stabilization (95% CI)
Total 97 (100) 54 (56)
Sex
Female 65 (67) 40 (62) 1 52 (80) 1
Male 32 (33) 14 (44) 0.49 (0.21–1.15) 0.10 21 (66) 0.48 (0.19–1.23) 0.12
Age (yr)
< 70 40 (41) 20 (50) 1 28 (70) 1
≥ 70 57 (59) 34 (60) 1.48 (0.65–3.34) 0.35 45 (79) 1.61 (0.64–4.07) 0.32
ECOG PS
0–2 77 (74) 48 (62) 1 64 (83) 1
3–4 20 (26) 6 (30) 0.26 (0.90–0.75) 0.009 9 (45) 0.17 (0.006–0.48) < 0.001
Smoking status
Never smoker 74 (76) 45 (61) 1 61 (82) 1
Current/former smoker 23 (24) 9 (39) 0.41 (0.16–1.08) 0.07 12 (52) 0.23 (0.08–0.64) 0.003
Histology
Adenocarcinoma 88 (91) 51 (58) 1 67 (76) 1
Non-adenocarcinoma 9 (9) 3 (33) 0.36 (0.09–1.55) 0.16 6 (67) 0.63 (0.14–2.73) 0.53
Stage
IIIB 24 (25) 15 (63) 1 22 (92) 1
IV 73 (75) 39 (53) 0.69 (0.27–1.77) 0.44 51 (70) 0.21 (0.05–0.98) 0.03
*Data presented as n (%) or mean (range). OR = odds ratio; CI = confidence interval; ECOG PS = European Cooperative Oncology
Group performance status.
Kaohsiung J Med Sci January 2010 • Vol 26 • No 14
C.T. Yang, J.Y. Hung, C.L. Lai, et al
Table 2. Overall survival in each subgroup of the patients
Mean follow 1-year HR 
Characteristics n
up time (wk) survival rate (%) (95% CI)
p
Total 97 43.2 77.34
Sex
Female 65 44.0 83.40 1
Male 32 41.0 66.40 2.34 (0.90–6.07) 0.08
Age (yr)
< 70 40 40.0 76.50 1
≥ 70 57 46.0 77.60 0.90 (0.34–2.37) 0.83
ECOG PS
0–2 77 47.0 90.60 1
3–4 20 30.0 15.30 8.32 (3.10–22.36) < 0.001
Smoking status
Never smoker 74 44.0 83.60 1
Current/former smoker 23 40.0 60.60 3.02 (1.16–7.85) 0.02
Histology
Adenocarcinoma 88 43.0 76.20 1
Non-adenocarcinoma 9 43.0 88.90 0.62 (0.08–4.66) 0.62
Stage 
IIIB 24 54.0 100 1
IV 73 40.0 68.60 7.36 (0.97–55.88) 0.053
Response
PD 24 36.14 45.90 1
SD 19 35.38 78 0.45 (0.14–1.42) 0.17
Partial response 54 49.09 94 0.06 (0.01–0.26) < 0.001
Disease stabilization
(PD + SD) 73 45.52 89.70 0.14 (0.05–0.38) < 0.001
HR = hazard ratio; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status; PD = progressive
disease; SD = stable disease.
Table 3. Multivariate models show the adjusted odds ratios for response and disease stabilization and adjusted hazard
ratios for survival status
Response Disease stabilization Death
Patient subset
OR (95% CI)
p
OR (95% CI)
p
HR (95% CI)
p
Sex (male vs. female) – – 2.11 (0.80–5.55) 0.13
Smoking (ever vs. never) 0.39 (0.14–1.06) 0.07 0.22 (0.07–0.65) 0.007 –
Histology
(non-adenocarcinoma 0.26 (0.06–1.16) 0.07 – –
vs. adenocarcinoma)
Stage (IIIB vs. IV) – – 5.21 (0.67–40.26) 0.11
ECOG PS 0.24 (0.08–0.72) 0.01 0.16 (0.05–0.49) 0.001 6.46 (2.40–17.43) < 0.001
OR = odd ratios; HR = hazard ratio; CI = confidence interval; ECOG PS = Eastern Cooperative Oncology Group performance status.
The multivariate models that included factors
with p value < 0.15 are shown in Table 3. For overall
response, we found that patients who had ever
smoked, had non-adenocarcinoma histology or poor
ECOG performance status were less likely to respond
to gefitinib, while patients who had ever smoked or
those with poor ECOG performance status were less
likely to show disease stabilization with gefitinib treat-
ment. For survival, we found that patients who were
male or patients with poor ECOG performance status
had poor survival when receiving gefitinib as first-line
treatment.
DISCUSSION
In this study, the overall response rate and disease
control rate were 56% and 76%, respectively, both of
which are higher than those in other reports [19–22],
where the response rates ranged from 15.2% to 42%,
and the disease control rates ranged from 25.8% to
60%. Gefitinib is effective in treating NSCLC patients
with EGFR gene mutations [23–26]. Females, never
smokers, adenocarcinoma histology and patients of
Asian origin are more likely to have such mutations
[26,27]. Although EGFR gene mutations were not
determined in this study, the linkage between EGFR
gene mutations and female sex, no smoking history,
adenocarcinoma and East Asian patients is well-
known. This may explain why the response rate and
the disease control rate in this study are still less than
those reported in the phase II study by Lee et al [15].
They reported better overall response (69%) and dis-
ease control (80%) rates for 37 patients with NSCLC (all
with adenocarcinoma histology, no smoking history
and predominantly female). Because our study was
conducted retrospectively by reviewing patients’ med-
ical charts between 2004 and 2006, pre-selection bias
should be considered for the high response rate and
disease control rate.
None of the well-known predictive factors in the lit-
erature, such as female sex, smoking status or histol-
ogy, significantly predicted the overall response or
disease stabilization associated with gefitinib in our
study. Although patients with these factors still
seemed to respond better to gefitinib than patients
without these factors in our study, only smoking sta-
tus was a statistically significant predictor for disease
stabilization (PD and SD). The small sample size and
selection bias might be reasons why these factors
were not statistically significant predictors.
ECOG performance status, originally not consid-
ered a predictive factor for overall response or dis-
ease stabilization, was thus correlated in this study.
Similarly, Hoang et al reported that performance sta-
tus and another five independent factors were cor-
related with response rate and survival time for
patients with stage IIIB or IV NSCLC receiving third-
generation chemotherapy regimens [28]. In addition,
in a recent study of chemotherapy-naive patients
with advanced or metastatic NSCLC treated with
gefitinib in East Asia, the overall response rate and dis-
ease stabilization rate for patients with good (ECOG
score, 0–2) versus poor performance status (ECOG
score, 3–4) were 52% versus 28% and 70% versus 45%,
respectively [21]. Thus the correlation between per-
formance status and overall response and disease sta-
bilization in patients with NSCLC treated with
gefitinib seems reasonable, although further studies
are warranted to validate its significance.
The log-rank test was used to compare the 1-year
survival rates in each subgroup. As above, patients
who never smoked or patients with better ECOG per-
formance status had a better survival after gefitinib
therapy. Although female patients had a better 1-year
survival rates than males (83.40% vs. 66.40%, p = 0.08),
statistical significance was not achieved, which could
be due to the small sample size of this study. Patients
with adenocarcinoma are predicted to show better sur-
vival than patients with other types of lung cancer [29].
Unfortunately, we did not achieve similar results to
other studies. The 1-year survival rates for patients
with adenocarcinoma and non-adenocarcinoma were
76.2% and 88.9%, respectively. Nine patients were
diagnosed with non-adenocarcinoma in this study.
One of these patients was diagnosed with squamous
cell carcinoma, and the other eight patients did not
have a definite histological diagnosis because of small
specimens, or only had cytological diagnosis. Some
of these patients might have had adenocarcinoma.
Thus the beneficial effects of adenocarcinoma might
not be validated in this study because of the small size
of the comparative group or the absence of a compar-
ative group.
Kaplan-Meier survival analysis also demonstrated
that patients with PR or SD had significantly better
survival than patients with PD. Multivariate analysis
showed that only patients with better performance
status had better treatment response and survival.
In this multicenter, retrospective analysis, gefitinib
showed excellent anti-tumor effects when prescribed
as first-line therapy against advanced or metastatic
NSCLC. Considering our data and the results from
other studies, first-line gefitinib monotherapy offers
a promising therapy for some subgroups of Asian
patients with NSCLC. Further randomized controlled
studies are needed to validate the effectiveness of
first-line gefitinib therapy and its cost-effectiveness
First-line gefitinib in Southern Taiwan
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compared with traditional first-line chemotherapeutic
regimens.
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Gefitinib，為表皮生長激素受體酪胺酸激酶的專一抑制劑，是第一個當非小細胞肺癌
病患在接受化學治療失敗之後，被核准可以使用的標靶治療藥物。過去曾有一些較小
型的臨床試驗證實 gefitinib 對於未曾接受過化學治療的病患也有療效。本研究之目
的在探討轉移與晚期非小細胞肺癌患者第一線即使用 gefitinib 這一標靶治療藥物時
之反應率、病患整體存活率與其預測因子。本文以回溯性方式蒐集南台灣 6 家醫院所
有在 2004 年 5 月至 2006 年 4 月接受 gefitinib為第一線治療之轉移與晚期非小細胞
肺癌患者，分析病患對藥物之反應率與病患存活率，及這二者與一些已知可預測因子
之相關性。本研究共收納 97 位患者，對藥物之反應率為 56%，疾病控制率為 76%。
在本研究中，只有病患之生活功能狀態與病患對於 gefitinib 是否產生反應有明顯相
關。在本研究中，以 gefitinib 為第一線藥物治療轉移與晚期非小細胞肺癌患者，病
患可以存活超過一年的機率為 77%。我們認為第一線使用單一藥物 gefitinib 來治療
特定族群之亞洲非小細胞肺癌病患是極具前景的。以控制隨機之臨床試驗進一步來驗
證第一線 gefitinib 之療效是必須的。
關鍵詞： gefitinib，非小細胞肺癌，標靶治療
(高雄醫誌 2010;26:1–7)
